Study highlights efficacy of Oral-B oscillating-rotating power toothbrush
CINCINNATI — In a four- to 12-week period, power brushes with oscillating-rotating technology, pioneered by Oral-B, reduce plaque and gingivitis more than power brushes that move laterally from side-to-side, known as sonic, according to the Cochrane Collaboration, an independent healthcare research group.
Furthermore, the analysis reiterated that no other powered designs are consistently superior to manual toothbrushes. This finding originally was reported in the Collaboration’s 2003 “Power versus Manual” toothbrush systematic review. The most recent report also found that oscillating-rotating technology alone consistently is superior at removing plaque and reducing gum inflammation in not only the short-term, but over the long-term as well.
Oral-B, a Procter & Gamble oral care brand, led the development of oscillating-rotating technology in 1991, and has since published more than 90 clinical studies demonstrating the superior efficacy of oscillating-rotating technology.
“Oral-B continuously aims to provide consumers and professionals with products that meet their needs and deliver superior oral health benefits,” stated Leslie Winston, global director of professional and scientific relations for P&G Oral Care. “The Collaboration’s conclusions that oscillating-rotating technology reduces more plaque and gingivitis than both manual brushing and side-to-side power brush technology are a testament to the innovation and research occurring at P&G Oral Care and Oral-B.”
In 2005, the Cochrane Collaboration reported that clinical research showed that rotating-oscillating toothbrushes reduced plaque and gingivitis more than manual toothbrushes. In 2011, a separate Cochrane review reported a small but significant difference in plaque and gingivitis reduction for oscillating-rotating power toothbrushes versus side-to-side power toothbrushes. The report did not reach any conclusion about the clinical importance of these results.
Oral-B enhanced its power toothbrush functionality and efficacy further by applying its 3D action to the ProfessionalCare power brush series. It combines oscillating-rotating technology with gentle in-and-out pulsations that have been shown to remove even more plaque than oscillating-rotating technology alone.
In addition, the company’s flagship model, the ProfessionalCare SmartSeries 5000 with SmartGuide, incorporates many compliance-enhancing features that maximize brushing performance and increase compliance by tracking how long a person brushes and by guiding users through the four quadrants of the mouth as they brush.
Patients who use the ProfessionalCare SmartSeries 5000 with SmartGuide are, on average, five times more likely to adhere to the two minutes twice a day brushing recommendations, and are less likely to use excessive brushing force. Research has shown that 92% of patients significantly will improve their brushing thoroughness in 30 days with the ProfessionalCare SmartSeries 5000 with SmartGuide.
Actavis donates drugs to Libya
ZEJTUN, Malta — Generic drug maker Actavis is donating 2 million euros worth of medicines to Libya, the company said.
Actavis announced the shipment of 170 pallets of medicines from Malta to the Libyan capital of Tripoli. The goods left Malta on Sunday and are scheduled to arrive in Tripoli this week. The products include cardiology, anti-infective, pain management and gastrointestinal drugs, among others.
"We know Libya is faced with shortages of essential supplies," Actavis Claudio Albrecht said. "That’s why Actavis donates 2 million euros worth of medicines to Libya now."
J&J pledges to recapture luster of McNeil OTC brands
NEW BRUNSWICK, N.J. — Johnson & Johnson Tuesday morning pledged significant support behind the relaunch of several McNeil Consumer products into the marketplace in 2012, and feels confident impacted brands — Tylenol and Motrin, among others — will be able to recapture market share, despite significant private-label erosion.
"One bit of data that we saw — even though private label has taken a particular amount of share in that part of the market is that trust of the McNeil brands among moms is still two-times the levels of competing products," J&J VP finance and CFO Dominic Caruso said during an analyst conference call Tuesday morning. Caruso told analysts the McNeil product relaunches would be reintroduced with a combination of brand marketing, couponing and dosing innovations to recapture its one-time loyal consumers. "We hope that the loyalty that these brands [have enjoyed] over the years will stay with us," Caruso said. Caruso projected the overall marketing and merchandising initiatives will elicit a "surround-sound impact and get the consumers back to the loyal consumers they were prior to the recall."
U.S. sales of over-the-counter medicines were significantly impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., J&J reported. Sales of the company’s OTC/nutritionals products were down 24.2% to $332 million. Two beauty products — Neutrogena and Dabao skin care products — were positive contributors to operational results, however. Within skin care, J&J reported a 20.9% lift to $376 million.
For the third quarter ended September, Johnson & Johnson reported U.S. sales of $6.9 billion, down 3.7% vs. the corresponding year-ago period. Sales were down across its U.S. businesses — consumer was down 4.5% to $1.2 billion; pharmaceutical was down 6.1% to $2.9 billion; and medical devices/diagnostics was down 0.8% to $2.8 billion.
J&J reported U.S. and international combined sales of $16 billion, an increase of 6.8% over the year-ago period.
In September, McNeil-PPC completed the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals in the United States. That business will be renamed McNeil Consumer Pharmaceuticals and will continue to market products under the Pepcid, Mylanta and Mylicon brands.